01.29.26 -- The Industrialization Of Advanced Modalities

As antibody formats grow more complex, transient expression often masks manufacturability risks that surface too late. In this webinar, Asimov introduces Rapid Pools, a high-throughput stable CHO platform that delivers early, CLD-relevant expression and quality data. Through two real-world case studies, learn how integrating stable pools into protein engineering improves predictability, rescues challenging molecules, and expands viable antibody design space. Click here to learn more.

By addressing considerations for a comprehensive reference standard strategy, manufacturers can ensure the integrity of biopharmaceuticals, ultimately paving the way for better patient outcomes.

Accelerate drug development and reduce risk with parallel operations. Learn how leveraging CDMO partnerships while building internal capabilities can cut costs and speed your path to market.

Gain expert insights on mitigating risks in global pharmaceutical manufacturing by learning from Joon Chang and Tracey Partington’s decades of industry experience.

Results show the multi-attribute method provided superior specificity and detected molecular modifications far better than the status quo.

Advanced computational methods coupled with bioinformatics can be used to navigate the complexities of bioprocessing by anticipating challenges before they arise.

Explore chromatography fundamentals, resin selection strategies, and the regulatory frameworks required to qualify automated systems for compliant, commercial-scale biologics manufacturing.

Unlock significant lab efficiency and financial gains. See how focused optimization of workflows and asset management led to substantial cost savings and reclaimed six-figure value in consumables.

Review the rapidly evolving world of complex drug development and the critical factors that drive success for products made using different molecules beyond the traditional antibodies.

Here, we present a hybridoma-based antibody discovery and humanization strategy for a T1P target, utilizing Penta Mice immunization to generate monoclonal antibodies.

Early functional screening boosts antibody discovery by improving hit rates and efficiency across hybridoma, single-B-cell, and phage display platforms.

Delve into strategies to improve the performance of IB processes as well as the pros and cons of soluble and insoluble processes: isolating, solubilizing, and properly refolding.

Grasp the strategy for achieving sustainable growth through organizational transformation. Systematic digitization and right-sized automation set the stage for next-level operational excellence.

Your breakthrough therapies deserve the support of a CMO as committed as you are. Together, we’ll help make your sterile injectable therapies reliable, patient-friendly, and within reach for patients globally.

Uncover more about the capacity of our new facility and how our highly automated cGMP capabilities can help produce your innovative therapeutic and reach patients in need.

A biotech developing first-in-class, clinical-stage cancer immunotherapies needed a CDMO to rapidly advance its third lead candidate from the ground up.

With deep industry expertise in both large- and small- molecule parenteral drug testing, this team can effectively manage your API, drug substance, and product stability study programs.

Join Outsourced Pharma Chief Editor Jeff Buguliskis and our panel of industry experts as they share practical advice, reveal what to look for beyond the surface, and answer your toughest questions about selecting a CDMO partner that can truly deliver. Register for free today!